FERROUS BISGLYCINATE 30MG + FOLIC ACID 100 MCG DROPS (IRON DROPS)
| Composition | FERROUS BISGLYCINATE 30MG + FOLIC ACID 100 MCG DROPS (IRON DROPS) |
|---|---|
| Dosage form | Drops |
| Speciality | General Range |
| Packing | 30ml |
| Company | Vismit Lifesciences |
FERMIVIT-XT DROPS is a paediatric formulation from Vismit Lifesciences, containing FERROUS BISGLYCINATE 30MG + FOLIC ACID 100 MCG DROPS (IRON DROPS).
Packing: 30ml
It is part of the Vismit Lifesciences Pediatric / Oral Suspension range and is available for PCD pharma franchise and distribution. Contact Vismit Lifesciences through this page for pricing, monopoly rights and product availability in your area.
PEPPERMINT 38.5%+ KAPOOR 38.5% + WINTER GREEN OIL 12.25 + QS BASE (ANTI COLD INH...
L-ARGININE 3 GM (100%) + DHA 100 MG + CYANOCOBALAMINE + GRAPE SEED EXT + FOLIC A...
Exclusive franchise rights for your area.
Visual aids, samples and marketing material.
A wide, ready-to-sell product range.
Fast dispatch and dependable supply.
Start your own pharma business with a small budget.
Help with orders, billing and product queries.
Tell us your city, experience and the range you want.
Get product list, prices and monopoly details.
Share GST & drug licence and finalise the agreement.
Receive your first order with promotional material.
Can't find your answer? Send your question — the company will reply.
Yes. Vismit Lifesciences offers PCD pharma franchise. Send an enquiry with your city to get the product list and franchise details.
Monopoly depends on availability in your district. Mention your city in the enquiry and the company will confirm.
A valid drug licence and GST registration are generally needed to start a PCD franchise.
Investment depends on the products and quantity you start with. The company will share the minimum order details with the product list.
Use the enquiry form on this page. Your requirement is shared with the company and they will get back to you.
Get monopoly rights, promotional support and quality products from Vismit Lifesciences.
